Literature DB >> 30779661

Multireader Determination of Clinically Significant Obstruction Using Hyperpolarized 129Xe-Ventilation MRI.

Lukas Ebner1,2, Rohan S Virgincar3, Mu He3,4, Kingshuk R Choudhury1, Scott H Robertson3,4, Andreas Christe2, Achille Mileto5, Joseph G Mammarapallil1, H Page McAdams1, Bastiaan Driehuys1,2,3,5, Justus E Roos6.   

Abstract

OBJECTIVE: The objective of our study was to identify the magnitude and distribution of ventilation defect scores (VDSs) derived from hyperpolarized (HP) 129Xe-MRI associated with clinically relevant airway obstruction.
MATERIALS AND METHODS: From 2012 to 2015, 76 subjects underwent HP 129Xe-MRI (48 healthy volunteers [mean age ± SD, 54 ± 17 years]; 20 patients with asthma [mean age, 44 ± 20 years]; eight patients with chronic obstructive pulmonary disease [mean age, 67 ± 5 years]). All subjects underwent spirometry 1 day before MRI to establish the presence of airway obstruction (forced expiratory volume in 1 second-to-forced vital capacity ratio [FEV1/FVC] < 70%). Five blinded readers assessed the degree of ventilation impairment and assigned a VDS (range, 0-100%). Interreader agreement was assessed using the Fleiss kappa statistic. Using FEV1/FVC as the reference standard, the optimum VDS threshold for the detection of airway obstruction was estimated using ROC curve analysis with 10-fold cross-validation.
RESULTS: Compared with the VDSs in healthy subjects, VDSs in patients with airway obstruction were significantly higher (p < 0.0001) and significantly correlated with disease severity (r = 0.66, p < 0.0001). Ventilation defects in subjects with airway obstruction did not show a location-specific pattern (p = 0.158); however, defects in healthy control subjects were more prevalent in the upper lungs (p = 0.014). ROC curve analysis yielded an optimal threshold of 12.4% ± 6.1% (mean ± SD) for clinically significant VDS. Interreader agreement for 129Xe-MRI was substantial (κ = 0.71).
CONCLUSION: This multireader study of a diverse cohort of patients and control subjects suggests a 129Xe-ventilation MRI VDS of 12.4% or greater represents clinically significant obstruction.

Entities:  

Keywords:  MRI; airway obstruction; asthma; chronic obstructive pulmonary disease (COPD); xenon

Mesh:

Substances:

Year:  2019        PMID: 30779661      PMCID: PMC7079551          DOI: 10.2214/AJR.18.20036

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  18 in total

Review 1.  Technical and analytical advances in pulmonary ventilation SPECT with xenon-133 gas and Tc-99m-Technegas.

Authors:  Kazuyoshi Suga
Journal:  Ann Nucl Med       Date:  2002-07       Impact factor: 2.668

2.  Dose and pulse sequence considerations for hyperpolarized (129)Xe ventilation MRI.

Authors:  Mu He; Scott H Robertson; S Sivaram Kaushik; Matthew S Freeman; Rohan S Virgincar; John Davies; Jane Stiles; William M Foster; H Page McAdams; Bastiaan Driehuys
Journal:  Magn Reson Imaging       Date:  2015-04-30       Impact factor: 2.546

3.  An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice.

Authors:  Helen K Reddel; D Robin Taylor; Eric D Bateman; Louis-Philippe Boulet; Homer A Boushey; William W Busse; Thomas B Casale; Pascal Chanez; Paul L Enright; Peter G Gibson; Johan C de Jongste; Huib A M Kerstjens; Stephen C Lazarus; Mark L Levy; Paul M O'Byrne; Martyn R Partridge; Ian D Pavord; Malcolm R Sears; Peter J Sterk; Stuart W Stoloff; Sean D Sullivan; Stanley J Szefler; Mike D Thomas; Sally E Wenzel
Journal:  Am J Respir Crit Care Med       Date:  2009-07-01       Impact factor: 21.405

4.  Extending semiautomatic ventilation defect analysis for hyperpolarized (129)Xe ventilation MRI.

Authors:  Mu He; S Sivaram Kaushik; Scott H Robertson; Matthew S Freeman; Rohan S Virgincar; H Page McAdams; Bastiaan Driehuys
Journal:  Acad Radiol       Date:  2014-09-26       Impact factor: 3.173

Review 5.  The role of hyperpolarized 129xenon in MR imaging of pulmonary function.

Authors:  Lukas Ebner; Jeff Kammerman; Bastiaan Driehuys; Mark L Schiebler; Robert V Cadman; Sean B Fain
Journal:  Eur J Radiol       Date:  2016-09-16       Impact factor: 3.528

6.  Which pulmonary function tests best differentiate between COPD phenotypes?

Authors:  Steve H Salzman
Journal:  Respir Care       Date:  2012-01       Impact factor: 2.258

7.  Hyperpolarized 3He MR for sensitive imaging of ventilation function and treatment efficiency in young cystic fibrosis patients with normal lung function.

Authors:  Elise Bannier; Katarzyna Cieslar; Karim Mosbah; Françoise Aubert; François Duboeuf; Zahir Salhi; Sophie Gaillard; Yves Berthezène; Yannick Crémillieux; Philippe Reix
Journal:  Radiology       Date:  2010-04       Impact factor: 11.105

8.  Hyperpolarized 129Xenon Magnetic Resonance Imaging to Quantify Regional Ventilation Differences in Mild to Moderate Asthma: A Prospective Comparison Between Semiautomated Ventilation Defect Percentage Calculation and Pulmonary Function Tests.

Authors:  Lukas Ebner; Mu He; Rohan S Virgincar; Timothy Heacock; Suryanarayanan S Kaushik; Matthew S Freemann; H Page McAdams; Monica Kraft; Bastiaan Driehuys
Journal:  Invest Radiol       Date:  2017-02       Impact factor: 6.016

9.  Hyperpolarized 3He and 129Xe MR imaging in healthy volunteers and patients with chronic obstructive pulmonary disease.

Authors:  Miranda Kirby; Sarah Svenningsen; Amir Owrangi; Andrew Wheatley; Adam Farag; Alexei Ouriadov; Giles E Santyr; Roya Etemad-Rezai; Harvey O Coxson; David G McCormack; Grace Parraga
Journal:  Radiology       Date:  2012-09-05       Impact factor: 11.105

Review 10.  Hyperpolarized Gas MR Imaging: Technique and Applications.

Authors:  Justus E Roos; Holman P McAdams; S Sivaram Kaushik; Bastiaan Driehuys
Journal:  Magn Reson Imaging Clin N Am       Date:  2015-05       Impact factor: 2.266

View more
  1 in total

Review 1.  In vivo methods and applications of xenon-129 magnetic resonance.

Authors:  Helen Marshall; Neil J Stewart; Ho-Fung Chan; Madhwesha Rao; Graham Norquay; Jim M Wild
Journal:  Prog Nucl Magn Reson Spectrosc       Date:  2020-12-09       Impact factor: 9.795

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.